CN Patent

CN104961680B — N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型

Assigned to Crystal Pharmatech Co Ltd · Expires 2017-09-12 · 9y expired

What this patent protects

本发明涉及N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑N’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型、它们的制备方法。本发明的式(Ⅰ)化合物的盐酸盐，其结晶存在着多晶型，并且，其溶解度比之苹果酸盐更高，对于提高药物的生物利用度、药物疗效及安全性具有重要意义。

USPTO Abstract

本发明涉及N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑N’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型、它们的制备方法。本发明的式(Ⅰ)化合物的盐酸盐，其结晶存在着多晶型，并且，其溶解度比之苹果酸盐更高，对于提高药物的生物利用度、药物疗效及安全性具有重要意义。

Drugs covered by this patent

Patent Metadata

Patent number
CN104961680B
Jurisdiction
CN
Classification
—
Expires
2017-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmatech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.